keyword
https://read.qxmd.com/read/38175186/opportunities-in-assessing-and-regulating-organohalogen-flame-retardants-ofrs-as-a-class-in-consumer-products
#1
JOURNAL ARTICLE
Xinrong Chen, Linda S Birnbaum, Michael A Babich, Jacob de Boer, Kimberly W White, Stanley Barone, Cathy Fehrenbacher, Heather M Stapleton
BACKGROUND: In 2015, the U.S. Consumer Product Safety Commission (CPSC) received and then, in 2017, granted a petition under the Federal Hazardous Substances Act to declare certain groups of consumer products as banned hazardous substances if they contain nonpolymeric, additive organohalogen flame retardants (OFRs). The petitioners asked the CPSC to regulate OFRs as a single chemical class with similar health effects. The CPSC later sponsored a National Academy of Sciences, Engineering, and Medicine (NASEM) report in 2019, which ultimately identified 161 OFRs and grouped them into 14 subclasses based on chemical structural similarity...
January 2024: Environmental Health Perspectives
https://read.qxmd.com/read/37415228/topology-and-adenocarcinoma-cell-localization-dataset-on-the-labyrinthin-diapeutic-biomarker
#2
JOURNAL ARTICLE
Ankit Sharma, Michael Babich, Tianhong Li, James A Radosevich
OBJECTIVE: The discovery and characterization of tumor associated antigens is increasingly important to advance the field of immuno-oncology. In this regard, labyrinthin has been implicated as a neoantigen found on the cell surface of adenocarcinomas. Data on the (1) topology, (2) amino acid (a.a.) homology analyses and (3) cell surface localization of labyrinthin by fluorescent activated cell sorter (FACS) are studied in support of labyrinthin as a novel, pan-adenocarcinoma marker. RESULTS: Bioinformatics analyses predict labyrinthin as a type II protein with calcium binding domain(s), N-myristoylation sites, and kinase II phosphorylation sites...
July 6, 2023: BMC Research Notes
https://read.qxmd.com/read/36765881/labyrinthin-expression-is-associated-with-poor-prognosis-in-patients-with-non-small-cell-lung-cancer
#3
JOURNAL ARTICLE
Weijie Ma, Jie Zeng, Dennis J Montoya, Kyra Toomey, Chihong Zhou, Shuai Chen, Dingning Liu, Michael Babich, James A Radosevich, Tianhong Li
To determine Labyrinthin (LAB) expression in non-small-cell lung cancer (NSCLC), we immunostained and scored for LAB immunohistochemistry (IHC) expression on sections of tissue microarrays (TMAs) prepared from 256 archival tissue blocks of NSCLC. Propensity-score-weighted Kaplan-Meier curves and weighted Cox models were used to associate LAB expression with overall survival. LAB mRNA expression was assessed in The Cancer Genome Atlas (TCGA) and correlated with clinical phenotype and outcome. Positive LAB IHC expression (>5% of tumor cells) was detected in 208/256 (81...
February 1, 2023: Cancers
https://read.qxmd.com/read/36655588/predictors-and-outcomes-of-palliative-care-consultations-for-patients-with-liver-disease-results-of-a-cohort-study-of-75-million-medical-records
#4
JOURNAL ARTICLE
Nabeeha Mohy-Ud-Din, Aslam Syed, Cristina Strahotin, Michael Babich
Background: Liver transplant is the only cure for cirrhosis. We studied the impact of palliative care on patient care by conducting a population-based cohort study. Methods: We queried the Explorys database (IBM, New York) database for a diagnosis of 'cirrhosis' followed by 'palliative care consultation' and collected demographic and clinical data. Results: We identified 316,970 patients with cirrhosis. Palliative care was consulted for 10.9% (n = 34,600) of patients. Patients aged >65 [OR 1.33 (1.30-1.36), P < ...
January 19, 2023: American Journal of Hospice & Palliative Care
https://read.qxmd.com/read/36571672/outcomes-of-octogenarians-and-nonagenarians-with-pseudomonas-aeruginosa-bacteremia-a-multicenter-retrospective-study
#5
MULTICENTER STUDY
Alaa Atamna, Ili Margalit, Gida Ayada, Tanya Babich, Pontus Naucler, John Karlsson Valik, Christian G Giske, Natividad Benito, Ruben Cardona, Alba Rivera, Celine Pulcini, Manal Abdel Fattah, Justine Haquin, Alasdair Macgowan, Bibiana Chazan, Anna Yanovskay, Ronen Ben Ami, Michal Landes, Lior Nesher, Adi Zaidman-Shimshovitz, Kate McCarthy, David L Paterson, Evelina Tacconelli, Michael Buhl, Susanna Mauer, Jesús Rodríguez-Baño, Marina de Cueto, Antonio Oliver, Enrique Ruiz de Gopegui, Angela Cano, Isabel Machuca, Monica Gozalo-Marguello, Luis Martinez-Martinez, Eva M Gonzalez-Barbera, Iris Gomez Alfaro, Miguel Salavert, Bojana Beovic, Andreja Saje, Manica Mueller-Premru, Leonardo Pagani, Virginie Vitrat, Diamantis Kofteridis, Maria Zacharioudaki, Sofia Maraki, Yulia Weissman, Mical Paul, Yaakov Dickstei, Dafna Yahav
BACKGROUND: P. aeruginosa bacteremia is a common and severe infection carrying high mortality in older adults. We aimed to evaluate outcomes of P. aeruginosa bacteremia among old adults (≥ 80 years). METHODS: We included the 464/2394 (19%) older adults from a retrospective multinational (9 countries, 25 centers) cohort study of individuals hospitalized with P. aeruginosa bacteremia. Bivariate and multivariable logistic regression models were used to evaluate risk factors for 30-day mortality among older adults...
August 2023: Infection
https://read.qxmd.com/read/35697897/development-of-a-flame-retardant-and-an-organohalogen-flame-retardant-chemical-inventory
#6
JOURNAL ARTICLE
Charles Bevington, Antony J Williams, Colin Guider, Nancy C Baker, Brian Meyer, Michael A Babich, Sayon Robinson, Ann Jones, Katherine A Phillips
There have been many attempts to compile comprehensive lists of flame retardants. However, this goal has proven challenging due to the heterogeneity of compounds that can be used as flame retardants coupled with changes in formulation chemistry over time. Flame retardants have been the focus of many recent existing hazard, exposure, and risk assessments. These assessments have been class-based or for individual chemical substances. Here, diverse sets of publicly available data sources from governmental organizations and the open literature were compiled to develop an inventory of chemicals used as flame retardants and organohalogen flame retardants...
June 13, 2022: Scientific Data
https://read.qxmd.com/read/35612693/duration-of-treatment-for-pseudomonas-aeruginosa-bacteremia-a-retrospective-study
#7
JOURNAL ARTICLE
Tanya Babich, Pontus Naucler, John Karlsson Valik, Christian G Giske, Natividad Benito, Ruben Cardona, Alba Rivera, Celine Pulcini, Manal Abdel Fattah, Justine Haquin, Alasdair Macgowan, Sally Grier, Bibiana Chazan, Anna Yanovskay, Ronen Ben Ami, Michal Landes, Lior Nesher, Adi Zaidman-Shimshovitz, Kate McCarthy, David L Paterson, Evelina Tacconelli, Michael Buhl, Susanna Mauer, Jesús Rodríguez-Baño, Marina de Cueto, Antonio Oliver, Enrique Ruiz de Gopegui, Angela Cano, Isabel Machuca, Monica Gozalo-Marguello, Luis Martinez-Martinez, Eva M Gonzalez-Barbera, Iris Gomez Alfaro, Miguel Salavert, Bojana Beovic, Andreja Saje, Manica Mueller-Premru, Leonardo Pagani, Virginie Vitrat, Diamantis Kofteridis, Maria Zacharioudaki, Sofia Maraki, Yulia Weissman, Mical Paul, Yaakov Dickstein, Leonard Leibovici, Dafna Yahav
INTRODUCTION: There is no consensus regarding optimal duration of antibiotic therapy for Pseudomonas aeruginosa bacteremia. We aimed to evaluate the impact of short antibiotic course. METHODS: We present a retrospective multicenter study including patients with P. aeruginosa bacteremia during 2009-2015. We evaluated outcomes of patients treated with short (6-10 days) versus long (11-15 days) antibiotic courses. The primary outcome was a composite of 30-day mortality or bacteremia recurrence and/or persistence...
August 2022: Infectious Diseases and Therapy
https://read.qxmd.com/read/33993273/combination-versus-monotherapy-as-definitive-treatment-for-pseudomonas-aeruginosa-bacteraemia-a-multicentre-retrospective-observational-cohort-study
#8
MULTICENTER STUDY
Tanya Babich, Pontus Naucler, John Karlsson Valik, Christian G Giske, Natividad Benito, Ruben Cardona, Alba Rivera, Celine Pulcini, Manal Abdel Fattah, Justine Haquin, Alasdair MacGowan, Sally Grier, Julie Gibbs, Bibiana Chazan, Anna Yanovskay, Ronen Ben Ami, Michal Landes, Lior Nesher, Adi Zaidman-Shimshovitz, Kate McCarthy, David L Paterson, Evelina Tacconelli, Michael Buhl, Susanna Mauer, Jesus Rodriguez-Bano, Isabel Morales, Antonio Oliver, Enrique Ruiz de Gopegui, Angela Cano, Isabel Machuca, Monica Gozalo-Marguello, Luis Martinez Martinez, Eva M Gonzalez-Barbera, Iris Gomez Alfaro, Miguel Salavert, Bojana Beovic, Andreja Saje, Manica Mueller-Premru, Leonardo Pagani, Virginie Vitrat, Diamantis Kofteridis, Maria Zacharioudaki, Sofia Maraki, Yulia Weissman, Mical Paul, Yaakov Dickstein, Leonard Leibovici, Dafna Yahav
BACKGROUND: Pseudomonas aeruginosa bacteraemia is a common and serious infection. No consensus exists regarding whether definitive combination therapy is superior to monotherapy. We aimed to evaluate the impact of combination therapy on mortality. METHODS: This was a multicentre retrospective study (nine countries, 25 centres), including 1277 patients with P. aeruginosa bacteraemia during 2009-15. We evaluated the association between β-lactam plus aminoglycoside or quinolone combination therapy versus β-lactam monotherapy and mortality...
July 15, 2021: Journal of Antimicrobial Chemotherapy
https://read.qxmd.com/read/33625610/gastroenterology-fellowship-applicants-perspectives-on-gi-program-preferences
#9
JOURNAL ARTICLE
Usman Tariq, Shifa Umar, Suzanne Morrissey, Michael Babich
Gastroenterology fellowship continues to be highly competitive among internal medicine subspecialties. Recruiting excellent applicants is also important for GI fellowship program directors. We aim to examine factors that influence GI fellowship applicants' perspectives about a fellowship program. The authors conducted an anonymous online survey of applicants focusing on program characteristics including location, faculty, research/clinical opportunities, website, and interview day experience. Anonymous survey responses were recorded regarding program characteristics, and subsequent candidate preferences were evaluated for factors influencing their decision...
April 2021: Digestive Diseases and Sciences
https://read.qxmd.com/read/32865839/meeting-report-from-the-prostate-cancer-foundation-psma-theranostics-state-of-the-science-meeting
#10
REVIEW
Andrea K Miyahira, Kenneth J Pienta, John W Babich, Neil H Bander, Jeremie Calais, Peter Choyke, Michael S Hofman, Steven M Larson, Frank I Lin, Michael J Morris, Martin G Pomper, Shahneen Sandhu, Howard I Scher, Scott T Tagawa, Scott Williams, Howard R Soule
INTRODUCTION: The Prostate Cancer Foundation (PCF) convened a PCF prostate-specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 November 2019, at Weill Cornell Medicine, New York, NY. METHODS: The meeting was attended by 22 basic, translational, and clinical researchers from around the globe, with expertise in PSMA biology, development and use of PSMA theranostics agents, and clinical trials. The goal of this meeting was to discuss the current state of knowledge, the most important biological and clinical questions, and critical next steps for the clinical development of PSMA positron emission tomography (PET) imaging agents and PSMA-targeted radionuclide agents for patients with prostate cancer...
November 2020: Prostate
https://read.qxmd.com/read/31917999/plasticizer-migration-from-children-s-toys-child-care-articles-art-materials-and-school-supplies
#11
JOURNAL ARTICLE
Michael A Babich, Charles Bevington, Matthew A Dreyfus
Dialkyl phthalates, including diisononyl phthalate (DINP), have been used as plasticizers in children's products made from polyvinyl chloride (PVC), such as teethers and toys. Children may be exposed to phthalates when handling or mouthing PVC products because plasticizers are not covalently bound. The Consumer Product Safety Improvement Act of 2008 prohibited certain phthalates from use in child care articles and children's toys. Thus, manufacturers have changed to other plasticizers or non-PVC plastics and there is interest in evaluating the potential health risks of alternative plasticizers...
March 2020: Regulatory Toxicology and Pharmacology: RTP
https://read.qxmd.com/read/31807015/labyrinthin-the-tumor-marker-recognized-by-mca-44-3a6-a-case-for-pan-tumor-markers-as-targets-to-treat-cancer
#12
REVIEW
James A Radosevich, Michael Babich
A paradigm shift is currently underway on the relationship between cancer treatment markers and therapies. Labyrinthin is a prime example of such a marker because it is a pan-cancer target for adenocarcinomas. This movement supports the idea that we must change our thinking from various cancer types (eg, lung, breast, colon) to "cancer arising" in a given tissue or organ. In doing so, this would further support the efforts toward pan-treatments rather than organ-specific treatments.
2019: OncoTargets and Therapy
https://read.qxmd.com/read/31770625/risk-factors-for-mortality-among-patients-with-pseudomonas-aeruginosa-bacteraemia-a-retrospective-multicentre-study
#13
MULTICENTER STUDY
Tanya Babich, Pontus Naucler, John Karlsson Valik, Christian G Giske, Natividad Benito, Ruben Cardona, Alba Rivera, Celine Pulcini, Manal Abdel Fattah, Justine Haquin, Alasdair MacGowan, Sally Grier, Bibiana Chazan, Anna Yanovskay, Ronen Ben Ami, Michal Landes, Lior Nesher, Adi Zaidman-Shimshovitz, Kate McCarthy, David L Paterson, Evelina Tacconelli, Michael Buhl, Susanna Maurer, Jesus Rodriguez-Bano, Isabel Morales, Antonio Oliver, Enrique Ruiz de Gopegui, Angela Cano, Isabel Machuca, Monica Gozalo-Marguello, Luis Martinez-Martinez, Eva M Gonzalez-Barbera, Iris Gomez Alfaro, Miguel Salavert, Bojana Beovic, Andreja Saje, Manica Mueller-Premru, Leonardo Pagani, Virginie Vitrat, Diamantis Kofteridis, Maria Zacharioudaki, Sofia Maraki, Yulia Weissman, Mical Paul, Yaakov Dickstein, Leonard Leibovici, Dafna Yahav
This study aimed to evaluate risk factors for 30-day mortality among hospitalised patients with Pseudomonas aeruginosa bacteraemia, a highly fatal condition. A retrospective study was conducted between 1 January 2009 and 31 October 2015 in 25 centres (9 countries) including 2396 patients. Univariable and multivariable analyses of risk factors were conducted for the entire cohort and for patients surviving ≥48 h. A propensity score for predictors of appropriate empirical therapy was introduced into the analysis...
February 2020: International Journal of Antimicrobial Agents
https://read.qxmd.com/read/31753246/drug-induced-liver-injury-resources-and-reporting-for-the-clinician
#14
REVIEW
Marisa Isaacson, Michael Babich
Although many risk factors for developing drug-induced liver injury (DILI) have been identified and more than 1000 medications and herbal and dietary supplements are known to cause liver dysfunction, idiosyncratic drug reactions remain unpredictable and erratic. Varying effects of individual drugs on the event cascade and patient genetic polymorphisms lead to different clinical presentations. Mechanisms and causality scales have been developed to guide the clinician in diagnosis, and several databases and registries are available for reference and reporting...
February 2020: Clinics in Liver Disease
https://read.qxmd.com/read/31323088/ceftazidime-carbapenems-or-piperacillin-tazobactam-as-single-definitive-therapy-for-pseudomonas-aeruginosa-bloodstream-infection-a-multisite-retrospective-study
#15
JOURNAL ARTICLE
Tanya Babich, Pontus Naucler, John Karlsson Valik, Christian G Giske, Natividad Benito, Ruben Cardona, Alba Rivera, Celine Pulcini, Manal Abdel Fattah, Justine Haquin, Alasdair Macgowan, Sally Grier, Julie Gibbs, Bibiana Chazan, Anna Yanovskay, Ronen Ben Ami, Michal Landes, Lior Nesher, Adi Zaidman-Shimshovitz, Kate McCarthy, David L Paterson, Evelina Tacconelli, Michael Buhl, Susanna Mauer, Jesus Rodriguez-Bano, Isabel Morales, Antonio Oliver, Enrique Ruiz De Gopegui, Angela Cano, Isabel Machuca, Monica Gozalo-Marguello, Luis Martinez Martinez, Eva M Gonzalez-Barbera, Iris Gomez Alfaro, Miguel Salavert, Bojana Beovic, Andreja Saje, Manica Mueller-Premru, Leonardo Pagani, Virginie Vitrat, Diamantis Kofteridis, Maria Zacharioudaki, Sofia Maraki, Yulia Weissman, Mical Paul, Yaakov Dickstein, Leonard Leibovici, Dafna Yahav
BACKGROUND: The optimal antibiotic regimen for Pseudomonas aeruginosa bacteremia is controversial. Although β-lactam monotherapy is common, data to guide the choice between antibiotics are scarce. We aimed to compare ceftazidime, carbapenems, and piperacillin-tazobactam as definitive monotherapy. METHODS: A multinational retrospective study (9 countries, 25 centers) including 767 hospitalized patients with P. aeruginosa bacteremia treated with β-lactam monotherapy during 2009-2015...
May 23, 2020: Clinical Infectious Diseases
https://read.qxmd.com/read/31293206/criminal-rico-fighting-corruption-and-fraud-in-big-pharma-united-states-v-michael-l-babich
#16
JOURNAL ARTICLE
Elaine Ortyl
No abstract text is available yet for this article.
March 2019: American Journal of Law & Medicine
https://read.qxmd.com/read/31268109/improved-synthesis-of-the-bifunctional-chelator-p-scn-bn-hopo
#17
JOURNAL ARTICLE
N V S Dinesh K Bhupathiraju, Ali Younes, Minhua Cao, Jafar Ali, Huseyin T Cicek, Kathryn M Tully, Shashikanth Ponnala, John W Babich, Melissa A Deri, Jason S Lewis, Lynn C Francesconi, Charles Michael Drain
The bifunctional ligand p-SCN-Bn-HOPO, which has four 1,2-hydroxypyridinone groups on a spermine backbone with an isothiocyanate linker, has been shown to be an efficient and stable chelator for Zr(iv) and, more importantly, the radioisotope 89Zr for use in radiolabeling antibodies for positron emission tomography (PET) imaging. Previous studies of 89Zr-HOPO-trastuzumab in mice showed low background, good tumor to organ contrast, and very low bone uptake which show p-SCN-Bn-HOPO to be an important next-generation bifunctional chelator for radioimmunoPET imaging with 89Zr...
July 17, 2019: Organic & Biomolecular Chemistry
https://read.qxmd.com/read/30656564/adherence-to-two-large-bore-intravenous-lines-in-acute-gastrointestinal-bleeding-is-low
#18
JOURNAL ARTICLE
Mohammad Bilal, Osama Alhajjar, Matthew Madisetty, Vamsi Kantamaneni, Shailendra Singh, Michael Babich, Anastasios Kapetanos
BACKGROUND: While the available literature recommends placement of two large-bore intravenous (2LBIV) lines in every patient presenting with acute GIB, the adherence and impact of this recommendation have never before been reported. AIMS: We designed a quality improvement project to assess whether the patients presenting to our institution with acute GIB have appropriate intravenous (IV) access or not. METHODS: We conducted a prospective, observational study, of all patients presenting to our emergency department with overt GIB over a 2-month period...
March 2019: Digestive Diseases and Sciences
https://read.qxmd.com/read/29862439/refractory-hypercalcemia-in-squamous-cell-carcinoma-of-the-esophagus-a-case-report-and-review-of-literature
#19
REVIEW
Hamza Arif, Moeezullah Beg, Sohaib Zahid, Moaz Sial, Aditya Talwar, Antonios Christou, Michael Babich
No abstract text is available yet for this article.
December 2019: Journal of Gastrointestinal Cancer
https://read.qxmd.com/read/27765793/a-precision-medicine-approach-to-the-rescue-of-function-on-malignant-calmodulinopathic-long-qt-syndrome
#20
JOURNAL ARTICLE
Worawan B Limpitikul, Ivy E Dick, David J Tester, Nicole J Boczek, Pattraranee Limphong, Wanjun Yang, Myoung Hyun Choi, Jennifer Babich, Deborah DiSilvestre, Ronald J Kanter, Gordon F Tomaselli, Michael J Ackerman, David T Yue
RATIONALE: Calmodulinopathies comprise a new category of potentially life-threatening genetic arrhythmia syndromes capable of producing severe long-QT syndrome (LQTS) with mutations involving CALM1, CALM2, or CALM3. The underlying basis of this form of LQTS is a disruption of Ca2+ /calmodulin (CaM)-dependent inactivation of L-type Ca2+ channels. OBJECTIVE: To gain insight into the mechanistic underpinnings of calmodulinopathies and devise new therapeutic strategies for the treatment of this form of LQTS...
January 6, 2017: Circulation Research
keyword
keyword
39990
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.